Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection

Nutr Neurosci. 2017 Jun;20(5):291-296. doi: 10.1080/1028415X.2015.1123378. Epub 2015 Dec 28.

Abstract

Objectives: Somatic symptoms are common in depressive disorder and are similar to sickness behaviors due to inflammatory activation after cytokine administration. Omega-3 polyunsaturated fatty acids (PUFAs) are natural anti-inflammatory agents and may reduce inflammation-induced behavioral changes. The aim of this study was to investigate the role of PUFAs on the development of somatic symptoms and depression in patients of hepatitis C virus infection (HCV) receiving interferon-alpha therapy (IFN-α) in a prospective manner.

Methods: In this 24-week, prospective cohort study, 43 patients with chronic HCV ongoing IFN-α therapy were assessed with the mini-international neuropsychiatric interview for major depressive episodes and neurotoxicity rating scale (NRS) for somatic symptoms.

Results: One-third later developed IFN-α-induced depression (depression (DEP) group). As compared to subjects without depression, DEP group had higher NRS scores (P < 0.001), lower eicosapentaenoic acid (EPA) levels (P = 0.038) at week 2. Somatic symptoms, regardless of painful/non-painful characteristics, had positive association with arachidonic acid (P < 0.05), and negative association with EPA (P < 0.05).

Conclusion: This study implies that early intervention with omega-3 PUFAs might be a promising strategy to prevent depression and somatic symptoms in patients receiving cytokine therapy.

Keywords: Depression; Omega-3; PUFAs; Painful symptoms; n-3.

MeSH terms

  • Adult
  • Cohort Studies
  • Depression / chemically induced*
  • Depression / epidemiology
  • Depression / prevention & control
  • Fatty Acids, Omega-3 / administration & dosage*
  • Fatty Acids, Unsaturated / blood*
  • Female
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Interferon-alpha / adverse effects*
  • Interferon-alpha / blood
  • Interferon-alpha / toxicity
  • Male
  • Medically Unexplained Symptoms*
  • Middle Aged
  • Prospective Studies

Substances

  • Fatty Acids, Omega-3
  • Fatty Acids, Unsaturated
  • Interferon-alpha